MR-BIO: a Study to Evaluate Changes in MR Imaging and Biological Parameters
Launched by UNIVERSITY OF MANCHESTER · May 25, 2021
Trial Information
Current as of May 13, 2025
Recruiting
Keywords
ClinConnect Summary
The MR-BIO study is looking at how cancer tumors and surrounding healthy tissues change during radiotherapy treatment. Researchers will use a special machine called the MR Linear accelerator (MR Linac), which combines imaging and treatment, to take detailed pictures of the tumor during each session. They aim to see if changes in these images, along with samples taken from blood, urine, or tissue, can help predict how well the treatment is working.
To participate, you should be at least 18 years old and receiving radiotherapy at The Christie NHS Foundation Trust. You'll need to provide consent and be able to give blood and urine samples weekly during your treatment. Healthy volunteers will also be included but will only help with the imaging process and won’t provide samples. All participants will continue with their usual follow-up care after treatment, and the study is currently recruiting patients of all genders. It's important to note that certain medical conditions may prevent eligibility, especially those affecting MRI safety.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Be willing and able to provide written consent. Over 18 years of age. Undergo and satisfy MRI Safety Screening Patient volunteers must be under the care of a clinical oncologist at The Christie NHS Foundation Trust and be planned to receive radiotherapy to the target site to be imaged.
- • Patient volunteers must be able to give blood and/or urine sample as required through the treatment period.
- • Non-patient (healthy) volunteers must have no known or suspected significant medical condition.
- Exclusion Criteria:
- The following apply to both patients and healthy volunteers:
- Any conditions that would be a contra-indication to MRI including:
- • Failure to satisfy MRI Safety Screening Form
- • Implanted pacemakers and/or pacing wires
- • Cochlear implants
- • Programmable hydrocephalus shunts
- • Ferromagnetic implants
- • Unable to tolerate MR scans
- • Known HIV or active HepB or C
- • Pregnancy Healthy volunteers must not be a member of the study team.
About University Of Manchester
The University of Manchester is a leading research institution known for its commitment to advancing healthcare through innovative clinical trials. With a strong emphasis on multidisciplinary collaboration, the university leverages its extensive expertise in biomedical research and clinical practice to develop and evaluate new therapies and interventions. The institution is dedicated to improving patient outcomes and public health by conducting rigorous, ethically sound trials that adhere to the highest standards of scientific integrity. Through its state-of-the-art facilities and a robust network of healthcare partnerships, the University of Manchester actively contributes to the global body of medical knowledge and the translation of research findings into clinical applications.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Manchester, Greater Manchester, United Kingdom
Patients applied
Trial Officials
Ananya Choudhury, PhD, FRCR, MRCP, MA, MB BChir,
Principal Investigator
The Christie NHS Foundation Trust
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials